Development of this evidence summary
This evidence summary was developed for NICE by Bazian Ltd. The integrated process statement sets out the process NICE uses to select topics for the evidence summaries for unlicensed/off-label medicines and how the summaries are developed, quality assured and approved for publication.
Lizzie Amis, Senior Public Involvement Adviser, Public Involvement Programme, NICE
Dr Sarah Blagden, Consultant/Senior Lecturer in Medical Oncology, Director of Phase I Cancer Trials, Imperial College London
Roche reviewed the evidence summary and provided additional technical information.